In 2020, EHA launched the Taskforce on Diversity, Equity, and Inclusion with an EHA Board mandate.

Dear GoCART community,  With more than 1500 CAR-T infusions registered in the EBMT registry, EHA and EBMT are proud to announce a series of scientific calls within Work Package 6: Scientific…

VIRTUAL: EHA-PTHiT Hematology Mini Tutorial April 12 -13, 2021 Meeting Chairs: Prof G Gaidano (European Hematology Association) Prof I Hus (Polish Society of Hematology and Transfusion) Prof T Robak (Polish Society of Hematology and Transfusion) As…

October 26-31, 2020 | Virtual Global Conference Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty,  R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell In the last…

October 26-31, 2020 | Virtual Global Conference Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty,  R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell In the last…

Dates: February 4-6, 2021 Chairs: H Einsele (EHA) & C Chabannon (EBMT) For the 3rd time now the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT)…

"We (women) need to empower ourselves, learn to be confident and understand that are many ways of being a successful researcher and leader. But to make this possible we need institutions and research associations to help us by providing secure networks, structures and resources that help in boosting this change.” - Dr Alba Maiques-Diaz (Spain).

T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.

This scientific meeting was organized together with the EHA Scientific Working Group on Immune Therapies for Hematological Disorders.

November 13, 2020 Meeting Chairs: Prof J Gribben (European Hematology Association) Prof G Stemmelin (Argentinian Society of Hematology) On November 13, EHA and the Argentinian Society of Hematology (SAH) kicked-off the second…

The European Hematology Association (EHA) has joined the European Cancer Organisation, a not-for-profit federation of organizations working in cancer at the European level. EHA’s membership application was approved by the General Assembly of the European Cancer Organisation on November 18, 2020.

Professor Willem E. Fibbe has been involved in EHA over a period of twenty years, starting as counselor from 2000-2004. From 2007-2009 he served as President of EHA and spent ten years as a member of the EHA Board. He has recently joined several committees including the Nomination Committee, Research Committee and the Governance Committee. Meet Prof Fibbe and learn about what he does and why he has been volunteering at EHA through all these years.

Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition

EHA has initiated a series of online workshops dedicated to guidelines (produced or endorsed by EHA) for diagnosis and treatment of hematologic diseases.

This second edition of HOPE Asia was presented together with the Sri Lanka College of Haematologists (SLCH) on October 16 and 17, 2020. HOPE Asia 2020 was originally planned in Colombo, but due to governmental restrictions this meeting was made fully virtual.